Drug development is a time consuming, complex, risky and expensive venture. There is an increasing requirement to find ways to accelerate and reduce the cost of decision making so that only the best candidate molecules progress to the later stages of drug development.
Imanova is a translational research company that specialises in applying positron emission tomography (PET) and magnetic resonance imaging (MRI) scanning techniques to improve productivity in early drug development and to help improve disease understanding.
Established in 2011 Imanova was formed in an innovative alliance between the UK's Medical Research Council, Imperial College London, King's College London and University College London to act as a conduit between academia and industry.
Since inception, Imanova has completed over 50 clinical studies and is in a unique position to facilitate productive, mutually beneficial relationships between academia and industry.
Clinical imaging in humans can help companies to improve productivity and de-risk their drug development process. Imanova provide world class translational medicine capabilities by bringing together world class scanning equipment, radio-ligand development and imaging research methodology. Depending on the requirement of the Imanova provides:
At Imanova, the clinical imaging portfolio is supported by an extensive range of preclinical services and other supporting technologies.
PET can help quantify and determine the biodistribution or target engagement of the candidate drug and understand the mechanisms of disease in vivo. Preclinical PET enables the Imanova scientists to:
The rodent imaging suite at Imanova houses a purpose built Siemens Inveon PET-CT scanner and supporting technologies. Imanova has implemented a broad range of disease models, and through its academic links has access to many more at short notice. All procedures are performed in accordance with the ASPA 1986 and EU directive 2010/63/EU.
We have extensive experience with supportive in vitro techniques, including autoradiography, radioligand binding and microscopy staining techniques, to correlate biological changes with quantitative imaging outcomes.
Biomarker is a “biological indicator” used to measure onset and progression of a disease or as a marker of drug safety such as body temperature, blood pressure and heart rate. Imaging biomarkers (i-Biomarker) are used at Imanova to:
Imaging biomarkers have the advantage of being non-invasive and can be used for early detection of diseases, patient stratification, and provide an objective assessment for the response to treatment.
The main limiting factor for using molecular imaging studies for early stage drug development decision-making is the lack of available biomarkers. Imanova is an advocate of using imaging as an integral part of clinical research to help understand the basis of disease and in the support of the drug development process and has a dedicated i-Biomarker discovery and development service.
Imanova has developed and implemented 21 imaging biomarkers to Good Manufacturing Practice (GMP) standard since its inception. We have the capability and experience to help identify, evaluate, develop and implement biomarker candidates for use in both preclinical models and clinical (in humans) studies.
In addition to neurosciences, Imanova offers i-Biomarker development for other key therapeutic areas including oncology, inflammation, cardiology and respiratory diseases.
Imanova Ltd. has not received any reviews.
Imanova Ltd. has not received any endorsements.